Lilly recently announced that its RET inhibitor, selpercatinib (loxo-292), has been granted priority review status by the U.S. FDA and is expected to accelerate its approval for the treatment of […]
Aprea Therapeutics is a Boston-based biopharmaceutical company focused on developing and commercializing innovative cancer therapies that reactivate the tumor suppressor protein p53. Recently, the company announced that the U.S. food […]
After A string of disappointing clinical trials targeting the amyloid β-protein(Aβ), researchers in the field of Alzheimer’s disease (AD) are paying more attention to the tau protein, another culprit in the disease. Like Aβ, […]
In a new study, researchers from Southern Methodist University and the University of Texas MD Anderson Cancer Center found that oleandrin can stop the spread of HTLV-1 by targeting a […]
PLoS Biol: Scientists reveal new mechanism of Rapamycin. doi: 10.1371 / journal.pbio.3000252 Recently, in a research report published in PLoS Biology, scientists from the University of Michigan revealed a new […]
Rapamycin (RAPA), also known as “sirolimus”, was first discovered by scientists in the soil of Easter Island, Chile in 1975 due to its strong antifungal properties. Rapamycin is a macrolide […]
Small cell lung cancer (SCLC) is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer cases. Among them, about three-quarters of patients with small […]
Concert Pharma recently released the results of its phase II clinical trial evaluating the dose range of the experimental deuterated CTP-543 for patients with moderate to severe alopecia areata, an […]
Despite the popularity in the development of histone deacelytase (HDAC) inhibitors, the indications of the five already approved HDAC inhibitor drugs on the market are limited to peripheral T-cell lymphoma […]
Introduction Programmed death-ligand 1 (PD-L1) is a protein that is highly expressed on the surface of many cancer cells. As PD-L1’s receptor, PD-1 belongs to the immunoglobulin superfamily and can […]